Synthesis and quantitative structure-activity relationships of N-(1- benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective σ1 receptor ligands

Journal of Medicinal Chemistry

Volumn 41, Issue 13, 1998, Pages 2361-2370

  Huang, Yunsheng ^a   Hammond, Philip S ^a   Whirrett, Brian R ^a   Kuhner, Ross J ^a   Wu, Li ^a   Childers, Steven R ^a   Mach, Robert H ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N (1 BENZYLPIPERIDIN 4 YL) 2 FLUOROPHENYLACETAMIDE; N (1 BENZYLPIPERIDIN 4 YL)PHENYLACETAMIDE; N (1 BENZYLPIPERIDIN 4 YL)PHENYLACETAMIDE DERIVATIVE; OPIATE AGONIST; PENTAZOCINE; PRECLAMOL; SIGMA 1 OPIATE RECEPTOR; SIGMA 1 OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; GUINEA PIG; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPTIC MEMBRANE;

ACETAMIDES; ACETANILIDES; ANIMALS; BENZAMIDES; BRAIN; GUINEA PIGS; LIGANDS; LIVER; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032543727     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980032l     Document Type: Article

References (45)

1. Martin, W. R.; Eades, C. E.; Thompson, J. A.; Happler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
2. 3H]phencyclidine in rat central nervous tissue: further characterization and technical considerations. Brain Res. 1983, 258, 277-284.
3. Quirion, R.; Chicheportiche, R.; Contreras, P. C.; Johnson, K. M.; Lodge, D.; Tam, S. W.; Woods, J. H.; Zukin, S. R. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 1987, 10, 444-446.
4. Walker, J. M.; Brown, W. D.; Walker, F. O.; Matsumoto, R. E.; De Costa, B.; Rice, K. R. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42, 355-402.
5. Bowen, W. D.; Hellewell, S. B.; McGarry, K. A. Evidence for a multi-site mode of the rat brain a receptor. Eur. J. Pharmacol. 1989, 163, 309-318.
6. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, J. M. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
7. Itzhak, Y.; Khouri, M. Regulation of the binding of σ- and phencyclidine (PCP)-receptor ligands in rat brain membranes by guanidine nucleotide and ions. Neurosci. Lett. 1988, 85, 147-152.
8. Beart, P. M.; O'Shea, R. D.; Mallack, D. T. Regulation of σ-receptors: high and low affinity agonist states, GTP shifts-and up-regulation by rimcazole and 1,3-di-(2-tolyl)guanidine. J. Neurochem. 1989, 53, 779-788.
9. Connick, J. H.; Hanlon, G.; Roberts, J.; France, L.; Fox, P. K.; Nicholson, C. D. Multiple σ binding sites in guinea-pig and rat brain membranes: G-protein interactions, Br. J. Pharmacol. 1992, 107, 726-731.
10. Hellewell, S. B.; Bowen, W. D. A sigma-like binding site in the rat pheochromocytoma (PC12) cells: decreased affinity for (+)benzomorphans and lower molecular weight suggest a different sigma receptor from that of quinea pig brain. Brain Res. 1990, 527, 244-253.
11. Menkel, M.; Terry, P.; Pontecorvo, M.; Katz, J. L.; Witkins, J. M. Selective σ ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 1991, 201, 251-252.
12. Walker, J. M.; Bowen, W. D.; Patrick, S. L.; Williams, W. E.; Mascarella, S. W.; Bai, X.; Carroll, F. I. A comparison of (-)deoxybenzomorphans devoid of opiate activity with their dextrarotatory phenolic counterparts suggests role of σ receptors in motor function. Eur. J. Pharmacol. 1993, 231, 61-68.
13. Mash, D. C.; Zabetian, C. Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 1992, 12, 195-205.
14. Rukert, N. G. H.; Schmidt, W. J. The σ receptor ligand 1,3-di(2-tolyl)guanidine in animal models of schizophrenia. Eur. J. Pharmacol. 1993, 233, 261-267.
15. Kanzaki, A.; Okumura, K.; Ujike, H.; Tsuchida, K.; Akiyama, K.; Otsuki, S. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1propyl)piperidine. J. Neural. Transm. 1992, 90, 137-144.
16. Weiser, S. D.; Patrick S. L.; Mascarella, S. W.; Downing-Park, J.; Bai, X.; Carroll, F. I.; Walker, J. M.; Patrick, R. L. Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of σ receptor ligands. Eur. J. Pharmacol. 1995, 275, 1-7.
17. 3H]dopamine release from rat striatal slices by sigma receptor ligands. J. Pharmacol Imp. Ther. 1994, 271, 212-219.
18. 1 receptor in (+)-N-allylnormetazocine stimulated hippocampal cholinergic functions in rats. Brain Res. 1995, 690, 200-206.
19. Gonzalez-Alvear, G. M.; Werling, L. L. Sigma receptor regulation of norepinephrine release from rat hippocampal slices. Brain Res. 1995, 673, 61-69.
20. Chien, C. C.; Pasternak, G. W. Selective antagonism of opioid analgesia by a sigma system. J. Pharmacol. Imp. Ther. 1994, 271, 1583-1590.
21. 1 system. Eur. J, Pharmacol. 1993, 250, R7-R8.
22. Chien, C. C.; Pasternak, G. W. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 1995, 190, 137-139.
23. Liu, Y.; Whitlock B. B.; Pultz, J. A.; Wolfe, S. A., Jr. Sigma-1 receptors modulate functional activity of rat spleocytes. J. Neuroimmunol. 1995, 59, 143-154.
24. Largent, B. L.; Wikstrom, H.; Snowman, A. M.; Synder, S. H. Novel antipsychotic drugs share high affinity for σ receptors. Eur. J. Pharmacol. 1988, 155, 345-347.
25. Snyder, S. H.; Largent, B. L. Receptor mechanism in antipsychotic drug action: focus on sigma receptors. J. Neuropsych Clin. Neurosci. 1989, 1, 7-15.
26. Goldstein, S. R.; Matsumoto, R. R.; Thompson, T. L.; Patrick, R. L.; Bowen, W. D.; Walker, J. M. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989, 4, 254-258.
27. Thomas, G. E.; Szucs, M.; Mammone, J. Y.; Bem, W. T.; Rush, M. D.; Johnson, F. E.; Coscia, C. T. Sigma and opioid receptors in human brain tumors. Life Sci. 1990, 46, 1279-1286.
28. Bem, W. T.; Thomas, G. E.; Mamone, J. Y.; Roman, S. M.; Levy, B. K.; Johnson, F. E.; Coscia, C, J. Overexpression of σ receptors in nonneural human tumors. Cancer Res. 1991, 51, 6558-6562.
29. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408-413.
30. 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997, 57, 156-161.
31. John, C. S.; Bowen, W. D.; Varma, V. M.; McAfee, J. G.; Moody, T. W. Sigma receptors are expressed in human non-small cell lung carcima. Life Sci. 1995, 56, 2385-2392.
32. Vilner, B. J.; DeCosta, B. R.; Bowen, W. D. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J. Neurosci. 1995, 15, 117-134.
33. Brent, P. J.; Pang, G. T. σ binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur. J. Pharmacol. 1995, 278, 151-160.
34. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity σ receptor ligand for potential imaging of breast cancer. Cancer Res. 1995, 55, 3022-3027.
35. Ye, Y.; Huang, Y.; Wang, Z.; Chen, S.; Tia, Y. Synthesis of new amino acid and peptide derivatives of estradiol and their binding affinities for the estrogen receptor. Steroids 1993, 58, 35-39.
36. The SAS System, SAS Institute Inc., SAS Campus Drive, Cary, NC 27513-2414.
37. Hansch, C.; Leo, A.; Hoekman, D. In Exploring QSAR: Hydrophobic, Electronic, and Steric Constants; Heller, S. R., Ed.; ACS Professional Reference Book Series; American Chemical Society: Washington, DC, 1995.
38. Hansch, C.; Leo, A. In Exploring QSAR: Fundamentals and Applications in Chemistry and Biology; Heller, S. R., Ed.; ACS Professional Reference Book Series; American Chemical Society: Washington, DC, 1995.
39. 2 receptors: in vitro binding studies and positron emission tomography Synapse 1996, 24, 322-333.
40. Carroll, F. I; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Martin, B. R.; May, F. L.; Sauss, C.; Paolo, D.; Wallace, P.; Walker, J. M.; Bowen, W. D. Enantiomaric N-substituted N-Normetazocines: A comparative study of affinities at σ, PCP, and μ opioid receptors, J. Med Chem. 1992 35, 2812-2818.
41. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur, J. Pharmacol. Mol. Pharmacol. Sect. 1994, 268, 9-18.
42. 2 receptors. Life Sci. 1995, 57, PL 57-62.
43. Bradford, M. M. A rapid and sensitive method for the quantifcation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
44. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-4022.
45. Hogberg, T.; Norinder, U. Quantitative structure-activity relationships and experimental design. In A Textbook of Drug Design and Development; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Harwood Academic Publishers: Amsterdam, 1996; pp 94-130.